How Safe Is Gilead Sciences Inc. and Its Dividend?
Image source: Getty Images.
If you're looking for a stock that looks ridiculously cheap and has a dividend to boot, thenGilead Sciences (NASDAQ: GILD)is definitely a contender. The company has grown earnings by a ridiculous 95% per year over the past three years, it trades for just 6 times trailing earnings, and it sports a solid 2.4% dividend yield.
So how safe is Gildead as an investment, and how safe is its dividend?
Let's start with the easy part: The dividend
If you're an income investor, there's no metric more important than free cash flow (FCF). This represents the amount of money a company generates from its business, minus capital expenditures. It is from FCF that dividends are paid; keeping tabs on it gives you an idea of how sustainable a dividend really is.
Over the past 12 months, the company has only used 15% of FCF to pay its dividend. That makes it incredibly safe, and it holds a lot of potential for future increases. Even back in 2013 -- when FCF was one-sixth of what it is now -- the company used less than 65% of FCF to pay its dividend.
Now on to the hard part: How safe is the company?
Most companies could never dream of such soaring FCF as Gilead enjoyed starting in 2014. But that's how things work in Big Pharma: You make one or two blockbuster drugs, and your income statement can change in the blink of an eye.
Our own Keith Speights did a great jobof breaking down the bull and bear arguments for Gilead, but I'll summarize below.
Gilead experienced its surge in 2014 thanks to a combination of its Hepatitis C drugs (Sovaldi and Harvoni) and its HIV treatments. Since then, Merck (NYSE: MRK) has brought Zepatier, a direct competitor with Harvoni, to market. Zepatier is priced below Harvoni, and this has caused sales of the latter to slump 29%. Because Hepatitis C drugs combine to provide over half of Gilead's sales, this has investors spooked.
On the other hand, Keith points out that Gildead has a number of promising drugs in the pipeline, including Hep C and HIV treatments, as well as a breakthrough treatment for nonalcoholic steatohepatitis that could, by some estimates, achieve $12 billion in annual sales. If any one of these pipeline drugs is a success, it could make today's price tag of just $78 per share look very cheap.
How to navigate such situations
I'm not an investor in Big Pharma; the industry is too unpredictable for me. That means I reduce my unexpected downside risks, but it also means I've missed out on some huge winners. Gilead, for example, gained more than 500% between 2011 and 2015.
If you feel comfortable investing in a company like Gilead, then the time looks right. The company trades for a rock-bottom valuation. While the risk of losing significant Hep C sales could keep shares down, there's a lot of potential in the company's pipeline right now. What's more, you'll be paid a solid and very safe dividend between now and when we see the results coming from the pipeline.
All things considered, that's not a bad deal.
A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here.
Brian Stoffel has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: short October 2016 $85 calls on Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.